Kazia Therapeutics Limited
KZIA
$3.82
-$0.11-2.80%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.52M | 758.90K | -- | -- | -- |
| Total Other Revenue | 113.90K | 57.20K | 600.00 | 600.00 | 600.00 |
| Total Revenue | 1.63M | 816.10K | 600.00 | 600.00 | 600.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.63M | 816.10K | 600.00 | 600.00 | 600.00 |
| SG&A Expenses | 8.91M | 7.38M | 5.89M | 5.81M | 5.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.33M | 16.57M | 12.91M | 14.50M | 16.25M |
| Operating Income | -18.69M | -15.75M | -12.91M | -14.49M | -16.25M |
| Income Before Tax | -17.76M | -14.14M | -10.59M | -12.19M | -13.94M |
| Income Tax Expenses | -177.70K | -178.30K | -180.10K | -180.50K | -182.40K |
| Earnings from Continuing Operations | -17.58 | -13.97 | -10.41 | -12.01 | -13.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.58M | -13.97M | -10.41M | -12.01M | -13.76M |
| EBIT | -18.69M | -15.75M | -12.91M | -14.49M | -16.25M |
| EBITDA | -17.47M | -14.52M | -11.66M | -13.25M | -14.99M |
| EPS Basic | -16.29K | -13.72K | -11.22K | -15.89K | -20.85K |
| Normalized Basic EPS | -20.63 | -18.96 | -17.42 | -23.31 | -29.56 |
| EPS Diluted | -16.29K | -13.72K | -11.22K | -15.89K | -20.85K |
| Normalized Diluted EPS | -20.63 | -18.96 | -17.42 | -23.31 | -29.56 |
| Average Basic Shares Outstanding | 2.11M | 1.98M | 1.85M | 1.66M | 1.47M |
| Average Diluted Shares Outstanding | 4.00K | 3.70K | 3.40K | 3.00K | 2.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |